Twist Bioscience reported Q2 EPS miss, exceeded revenue estimates, and raised FY 2024 guidance.
Twist Bioscience (TWST) reported a Q2 earnings miss with EPS of ($1.47) vs. consensus estimate of ($0.76), but revenue of $81.5M exceeded estimates. The company updated its FY 2024 guidance for EPS and Q4 2024 guidance. Despite the earnings miss, NASDAQ:TWST stock traded up $2.36, reaching $45.33. Insiders have sold 11,289 shares in the past 90 days. Analysts at JPMorgan, Evercore, Scotiabank, Guggenheim, and TD Cowen provided updated price targets and ratings. Twist Bioscience Corporation, which manufactures and sells synthetic DNA-based products, saw its revenue increase by 27.7% year-over-year.
August 05, 2024
3 Articles